N85.01
Benign endometrial hyperplasia
Clinical Classification Guidelines
Inclusion Terms
- Endometrial hyperplasia (complex) (simple) without atypia
Medical Intelligence & Overview
Benign endometrial hyperplasia is a condition characterized by the abnormal thickening of the endometrial lining, which is the tissue lining the inside of the uterus. Classified as non-cancerous and without cellular atypia, this condition involves an increase in the number of endometrial glands, leading to a thicker uterine lining. It is often associated with hormonal imbalances, particularly excess estrogen, and may cause symptoms such as abnormal uterine bleeding. Recognizing this condition is crucial for appropriate management and monitoring, especially because it can sometimes be mistaken for more serious conditions if not properly diagnosed.
Causes & Symptoms
Clinical Causes: Unopposed Estrogen Exposure: Conditions that lead to elevated estrogen levels without the balancing effect of progesterone, such as obesity, polycystic ovary syndrome (PCOS), or hormone therapy. Irregular Ovulation: Irregular or absent ovulation can result in prolonged estrogen stimulation of the endometrium. Perimenopause or Menopause: Fluctuating hormone levels during these periods can contribute to hyperplasia. Hormonal Imbalances: Conditions affecting hormone production, including certain tumors or endocrine disorders. Use of Hormonal Medications: Estrogen-only hormone replacement therapy without progesterone support.
Key Symptoms: Irregular or abnormal uterine bleeding, including heavy periods or bleeding between periods. Spotting after menopause. Prolonged menstrual periods. Pelvic discomfort or pressure (less commonly). Asymptomatic in some cases, where the condition is discovered incidentally during routine examinations.
Diagnostic & Treatment
Diagnosis Path: Endometrial biopsy: A sample of the uterine lining is collected and examined microscopically to confirm hyperplasia. Ultrasound imaging: Transvaginal ultrasound is used to assess the thickness of the endometrium. Hysteroscopy: A procedure that allows direct visualization of the uterine cavity, often accompanied by tissue sampling. Dilation and curettage (D&C): A surgical procedure to remove tissue from the uterus for further examination, especially if biopsy results are inconclusive.
Treatment Protocols: Hormonal Therapy: Progestin therapy, which can be administered orally or via intrauterine devices, helps counteract estrogen stimulation and reduce endometrial thickness. Monitoring: Regular follow-up with ultrasounds and biopsy may be recommended for some patients to monitor the condition. Lifestyle Modifications: Weight management, exercise, and nutritional adjustments to balance hormones and reduce estrogen levels. Surgical Options: In cases where hyperplasia persists or progresses, procedures such as hysterectomy may be considered, especially if the condition is complex hyperplasia without atypia that does not resolve with medical therapy.
Clinical Advice & FAQs
Billing Guidance
Is N85.01 a billable ICD-10 code?
Yes, N85.01 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report N85.01?
Clinical documentation must specify the nature of Benign endometrial hyperplasia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference